Literature DB >> 33322384

PPARs and Myocardial Infarction.

Kay-Dietrich Wagner1, Nicole Wagner1.   

Abstract

Peroxisome proliferator-activated receptors (PPARs) belong to the nuclear hormone receptor family. They are ligand-activated transcription factors and exist in three different isoforms, PPARα (NR1C1), PPARβ/δ (NR1C2), and PPARγ (NR1C3). PPARs regulate a variety of functions, including glucose and lipid homeostasis, inflammation, and development. They exhibit tissue and cell type-specific expression patterns and functions. Besides the established notion of the therapeutic potential of PPAR agonists for the treatment of glucose and lipid disorders, more recent data propose specific PPAR ligands as potential therapies for cardiovascular diseases. In this review, we focus on the knowledge of PPAR function in myocardial infarction, a severe pathological condition for which therapeutic use of PPAR modulation has been suggested.

Entities:  

Keywords:  angiogenesis; cardiomyocytes; cardiovascular disease; endothelial cells; myocardial infarction; peroxisome proliferator-activated receptor

Year:  2020        PMID: 33322384      PMCID: PMC7764190          DOI: 10.3390/ijms21249436

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  79 in total

1.  Dual PPARα/γ ligand TZD18 improves myocardial metabolic remodeling after myocardial infarction in rats.

Authors:  X-L Chen; Z-R Liu; Y-J Xue; X Chen
Journal:  Eur Rev Med Pharmacol Sci       Date:  2017-12       Impact factor: 3.507

2.  Chrysin rescues rat myocardium from ischemia-reperfusion injury via PPAR-γ/Nrf2 activation.

Authors:  Neha Rani; Dharamvir Singh Arya
Journal:  Eur J Pharmacol       Date:  2020-07-22       Impact factor: 4.432

3.  Myocardial salvaging effect of telmisartan in experimental model of myocardial infarction.

Authors:  Sameer Goyal; Sachin Arora; Rajan Mittal; Sujata Joshi; Tapas C Nag; Ruma Ray; Santosh Kumari; Dharamvir Singh Arya
Journal:  Eur J Pharmacol       Date:  2009-08-05       Impact factor: 4.432

4.  Open-chest 31P magnetic resonance spectroscopy of mouse heart at 4.7 Tesla.

Authors:  Joseph Lee; Qingsong Hu; Yasuhiro Nakamura; Xiaohong Wang; Xiaoliang Zhang; Xiaohong Zhu; Wei Chen; Qinglin Yang; Jianyi Zhang
Journal:  J Magn Reson Imaging       Date:  2006-12       Impact factor: 4.813

5.  Preventive effect of hesperidin modulates inflammatory responses and antioxidant status following acute myocardial infarction through the expression of PPAR‑γ and Bcl‑2 in model mice.

Authors:  Chunying Meng; Zeheng Guo; Dagang Li; Hanwei Li; Jianbin He; Dingguo Wen; Bin Luo
Journal:  Mol Med Rep       Date:  2017-11-06       Impact factor: 2.952

6.  Adiponectin: an indispensable molecule in rosiglitazone cardioprotection following myocardial infarction.

Authors:  Ling Tao; Yajing Wang; Erhe Gao; Hangxiang Zhang; Yuexing Yuan; Wayne B Lau; Lawrence Chan; Walter J Koch; Xin L Ma
Journal:  Circ Res       Date:  2009-11-25       Impact factor: 17.367

7.  Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.

Authors:  Stephen C Benson; Harrihar A Pershadsingh; Christopher I Ho; Amar Chittiboyina; Prashant Desai; Michal Pravenec; Nianning Qi; Jiaming Wang; Mitchell A Avery; Theodore W Kurtz
Journal:  Hypertension       Date:  2004-03-08       Impact factor: 10.190

8.  Association between PPARalpha gene polymorphisms and myocardial infarction.

Authors:  Wibke Reinhard; Klaus Stark; Kamil Sedlacek; Marcus Fischer; Andrea Baessler; Katharina Neureuther; Stefan Weber; Bernhard Kaess; Silke Wiedmann; Stefan Mitsching; Wolfgang Lieb; Jeanette Erdmann; Christa Meisinger; Angela Doering; Ralf Tolle; Andreas Jeron; Guenter Riegger; Christian Hengstenberg
Journal:  Clin Sci (Lond)       Date:  2008-11       Impact factor: 6.124

9.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

Authors:  Steven E Nissen; Kathy Wolski
Journal:  N Engl J Med       Date:  2007-05-21       Impact factor: 91.245

Review 10.  PPARs and Angiogenesis-Implications in Pathology.

Authors:  Nicole Wagner; Kay-Dietrich Wagner
Journal:  Int J Mol Sci       Date:  2020-08-10       Impact factor: 5.923

View more
  4 in total

Review 1.  Peroxisome Proliferator-Activated Receptors and the Hallmarks of Cancer.

Authors:  Nicole Wagner; Kay-Dietrich Wagner
Journal:  Cells       Date:  2022-08-05       Impact factor: 7.666

2.  Gpx3 and Egr1 Are Involved in Regulating the Differentiation Fate of Cardiac Fibroblasts under Pressure Overload.

Authors:  Guoxing Li; Yuhong Qin; Zhe Cheng; Xiaocheng Cheng; Ruiyu Wang; Xuexiu Luo; Yipin Zhao; Dongying Zhang; Gang Li
Journal:  Oxid Med Cell Longev       Date:  2022-06-28       Impact factor: 7.310

3.  Rosiglitazone alleviates lipopolysaccharide-induced inflammation in RAW264.7 cells via inhibition of NF-κB and in a PPARγ-dependent manner.

Authors:  Jing-Ping Zhou; Xiao-Ning Yang; Yang Song; Fei Zhou; Jing-Jing Liu; Yi-Qun Hu; Li-Gang Chen
Journal:  Exp Ther Med       Date:  2021-05-11       Impact factor: 2.447

4.  The Editor's Choice Articles-Section "Cells of the Cardiovascular System" 2020-2021.

Authors:  Kay-Dietrich Wagner
Journal:  Cells       Date:  2022-07-11       Impact factor: 7.666

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.